https://www.selleckchem.com/pr....oducts/elexacaftor.h
Sodium zirconium cyclosilicate (SZC) is an oral potassium binder approved to treat hyperkalemia in adults in a number of countries, including Japan. This phase 2/3, randomized, double-blind, placebo-controlled, dose-response study (ClinicalTrials.gov NCT03127644) was designed to determine the efficacy and safety of SZC in Japanese adults with hyperkalemia. Patients with serum potassium (sK ) concentrations ≥ 5.1- ≤ 6.5mmol/L were randomized 111 to SZC 5g, SZC 10g, or placebo three times daily for 48h (six doses total). The primary e
Like
Comment
Share
